Assessment of a Therapeutic Device for Treatment of Acute Lung Injury Using a Combat-Relevant Porcine Model
Abstract
Acute lung injury (ALI) occurs in >30% of combat casualties. Inflammation is a key component and therapeutic strategies to block it are expected to decrease morbidity/mortality. Investigations directed at ways to limit activation and accumulation of leukocytes at sites of inflammation may prove clinically effective. Scope/Aims. Modulating neutrophil and monocyte/macrophage activity, the effector cells of the innate immune system, is a novel approach to diminish inflammation-induced disease processes without interfering with other immunologic activity, thereby avoiding adverse side effects. Innovative BioTherapies developed a selective cytopheretic device (SCD)therapy (Rx), to address this unmet medical need. SCDRx has been shown to improve clinical outcomes of critically ill patients with multiorgan failure by mitigating the inflammatory cascade. Specific Aim 1. Optimize a two-hit porcine ALI model relevant to combat situations. Specific Aim 2. Assess efficacy of 24h SCDRx in the porcine model. Progress to date. Yr1: Animal approvals obtained. 17 studies conducted yielding study and analysis protocols (Aim 1 met). Yr2: Assessment of SCDRx efficacy in porcine model. 17 studies conducted and significant therapeutic benefit was observed (Aim 2 initiated). Yr3 and NCE: Continued assessment of SCDRx efficacy. 13 studies conducted. The project has been completed in its entirety.
Document Details
- Document Type
- Technical Report
- Publication Date
- Dec 01, 2020
- Accession Number
- AD1133871
Entities
People
- H. D. Humes
- Jeffrey Curtis
- Kimberly A Johnston